EBR Systems (ASX:EBR), developer of a wireless cardiac pacing device for heart failure, disclosed it surpassed its 100th commercial WiSE implant and completed the first two tranches of a fully underwritten A$150 million capital raise during the quarter ended 30 June 2026, according to the company's Quarterly Activity Report and Form 10-Q submission.
Key Points
- EBR surpassed its 100th commercial WiSE implant, with total commercial implants reaching 117 across the pilot launch phase and Limited Market Release.
- The company secured purchasing agreements with HCA Healthcare, Advocate Health and CHRISTUS Health during the quarter.
- CMS formally initiated the National Coverage Determination process for the WiSE System through the TCET program in June 2026.
- EBR held cash, cash equivalents, restricted cash and marketable securities of US$89.5 million (A$130.1 million) as at 30 June 2026.
- The final A$35 million underwritten tranche of the capital raise is expected to be completed by 24 August 2026.
Commercial WiSE Implant Activity in Q2 2026
The WiSE System was implanted in 46 commercial patients during the quarter ended 30 June 2026, bringing total commercial implants across the pilot launch phase and Limited Market Release to 117. Multiple sites performed their first WiSE implants during the quarter, including Endeavor Health Evanston Hospital, North Carolina Baptist Hospital, The Ohio State University, University Medical Center New Orleans and University of Kansas Hospital. A total of 90 physicians at 30 sites are now trained to implant the WiSE System, with 26 trained during Q2 2026. An additional 17 purchase agreements were signed with target centres during the quarter, adding to the 35 signed in previous quarters.
Purchasing Agreements With Major US Healthcare Networks
During the quarter, EBR secured purchasing agreements with HCA Healthcare, Advocate Health and CHRISTUS Health. The HCA Healthcare agreement provides a purchasing pathway across a network comprising 190 hospitals and approximately 2,500 ambulatory sites of care across 19 states. Advocate Health is described in the filing as the third-largest non-profit integrated health system in the United States, with the agreement covering 69 hospitals across eight states. CHRISTUS Health is described as the ninth-largest hospital network in the United States, with the agreement establishing a purchasing pathway across a network of 66 hospitals.
CMS National Coverage Determination and Capital Raise Progress
In June 2026, the U.S. Centers for Medicare & Medicaid Services formally initiated a National Coverage Determination to evaluate Medicare coverage for leadless left ventricular endocardial pacing used in cardiac resynchronization therapy. The NCD initiation is described in the filing as a key outcome of EBR's engagement with CMS through the TCET pathway. EBR also disclosed it commenced transition into a new manufacturing facility in Santa Clara, California, and remains on track to vacate its legacy facility in Sunnyvale by year end. The company completed the first two tranches of the A$150 million capital raise, with the final A$35 million tranche expected to close by 24 August 2026.



Please wait processing your request...